用索拉非尼-对甲苯磺酸盐成功治疗一只未完全切除的输尿管细胞癌。

IF 1.5 4区 农林科学 Q2 VETERINARY SCIENCES Journal of the American Animal Hospital Association Pub Date : 2024-11-01 DOI:10.5326/JAAHA-MS-7463
Dongheon Shin, Chaerin Kim, Yeon Chae, Taesik Yun, Byeong-Teck Kang, Kyung-Mee Park, Hakhyun Kim
{"title":"用索拉非尼-对甲苯磺酸盐成功治疗一只未完全切除的输尿管细胞癌。","authors":"Dongheon Shin, Chaerin Kim, Yeon Chae, Taesik Yun, Byeong-Teck Kang, Kyung-Mee Park, Hakhyun Kim","doi":"10.5326/JAAHA-MS-7463","DOIUrl":null,"url":null,"abstract":"<p><p>Most urinary bladder (UB) tumors are malignant, and transitional cell carcinoma (TCC) is the most common neoplasm affecting the UB in dogs. Sorafenib may be a potential therapeutic agent for canine TCC. A 12 yr old spayed female Maltese dog weighing 3.6 kg and with a history of hematuria was referred for a suspected UB tumor. Abdominal ultrasonography revealed a UB mass attached to the cranioventral wall. The remaining abdominal examinations, including that of the lymph nodes, were unremarkable. Ultrasound-guided traumatic catheterization of the UB mass was performed, and the cytological evaluation of the UB mass indicated TCC. Excision was performed by partial cystectomy, and histopathology confirmed TCC, although the tumor had infiltrated the surgical margins. A chemosensitivity assay was conducted using tissue from the excised tumor. Sorafenib tosylate, a tyrosine kinase inhibitor, showed the greatest effect in the chemosensitivity assay. Therefore, adjuvant chemotherapy with sorafenib tosylate and piroxicam was administered postoperatively. The dog lived without any clinical signs, including hematuria or tumor relapse, for more than 2 yr after the surgery. This is the first report of successful long-term management of TCC with sorafenib tosylate in a dog.</p>","PeriodicalId":17185,"journal":{"name":"Journal of the American Animal Hospital Association","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Successful Management of Incompletely Resected Transitional Cell Carcinoma with Sorafenib Tosylate in a Dog.\",\"authors\":\"Dongheon Shin, Chaerin Kim, Yeon Chae, Taesik Yun, Byeong-Teck Kang, Kyung-Mee Park, Hakhyun Kim\",\"doi\":\"10.5326/JAAHA-MS-7463\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Most urinary bladder (UB) tumors are malignant, and transitional cell carcinoma (TCC) is the most common neoplasm affecting the UB in dogs. Sorafenib may be a potential therapeutic agent for canine TCC. A 12 yr old spayed female Maltese dog weighing 3.6 kg and with a history of hematuria was referred for a suspected UB tumor. Abdominal ultrasonography revealed a UB mass attached to the cranioventral wall. The remaining abdominal examinations, including that of the lymph nodes, were unremarkable. Ultrasound-guided traumatic catheterization of the UB mass was performed, and the cytological evaluation of the UB mass indicated TCC. Excision was performed by partial cystectomy, and histopathology confirmed TCC, although the tumor had infiltrated the surgical margins. A chemosensitivity assay was conducted using tissue from the excised tumor. Sorafenib tosylate, a tyrosine kinase inhibitor, showed the greatest effect in the chemosensitivity assay. Therefore, adjuvant chemotherapy with sorafenib tosylate and piroxicam was administered postoperatively. The dog lived without any clinical signs, including hematuria or tumor relapse, for more than 2 yr after the surgery. This is the first report of successful long-term management of TCC with sorafenib tosylate in a dog.</p>\",\"PeriodicalId\":17185,\"journal\":{\"name\":\"Journal of the American Animal Hospital Association\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the American Animal Hospital Association\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://doi.org/10.5326/JAAHA-MS-7463\",\"RegionNum\":4,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"VETERINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Animal Hospital Association","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.5326/JAAHA-MS-7463","RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

摘要

大多数膀胱(UB)肿瘤都是恶性的,而过渡细胞癌(TCC)是影响犬膀胱的最常见肿瘤。索拉非尼可能是治疗犬 TCC 的潜在药物。一只 12 岁的绝育雌性马尔济斯犬体重 3.6 千克,曾有血尿病史,因怀疑患有 UB 肿瘤而转诊。腹部超声波检查发现颅腹壁上有一个UTB肿块。包括淋巴结在内的其他腹部检查均无异常。在超声引导下对膀胱肿块进行了创伤性导管插入术,膀胱肿块的细胞学评估显示为 TCC。通过膀胱部分切除术进行了切除,组织病理学证实为 TCC,尽管肿瘤已浸润到手术边缘。利用切除的肿瘤组织进行了化疗敏感性检测。在化疗敏感性试验中,酪氨酸激酶抑制剂索拉非尼(Sorafenib tosylate)的效果最佳。因此,术后对该犬进行了索拉非尼 tosylate 和吡罗昔康的辅助化疗。该犬在术后 2 年多的时间里没有出现任何临床症状,包括血尿或肿瘤复发。这是首例成功使用甲磺酸索拉非尼长期治疗犬 TCC 的报告。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Successful Management of Incompletely Resected Transitional Cell Carcinoma with Sorafenib Tosylate in a Dog.

Most urinary bladder (UB) tumors are malignant, and transitional cell carcinoma (TCC) is the most common neoplasm affecting the UB in dogs. Sorafenib may be a potential therapeutic agent for canine TCC. A 12 yr old spayed female Maltese dog weighing 3.6 kg and with a history of hematuria was referred for a suspected UB tumor. Abdominal ultrasonography revealed a UB mass attached to the cranioventral wall. The remaining abdominal examinations, including that of the lymph nodes, were unremarkable. Ultrasound-guided traumatic catheterization of the UB mass was performed, and the cytological evaluation of the UB mass indicated TCC. Excision was performed by partial cystectomy, and histopathology confirmed TCC, although the tumor had infiltrated the surgical margins. A chemosensitivity assay was conducted using tissue from the excised tumor. Sorafenib tosylate, a tyrosine kinase inhibitor, showed the greatest effect in the chemosensitivity assay. Therefore, adjuvant chemotherapy with sorafenib tosylate and piroxicam was administered postoperatively. The dog lived without any clinical signs, including hematuria or tumor relapse, for more than 2 yr after the surgery. This is the first report of successful long-term management of TCC with sorafenib tosylate in a dog.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.70
自引率
0.00%
发文量
57
审稿时长
18-36 weeks
期刊介绍: The purpose of the JAAHA is to publish relevant, original, timely scientific and technical information pertaining to the practice of small animal medicine and surgery.
期刊最新文献
2022 AAHA Canine Vaccination Guidelines (2024 Update). 2024 AAHA Community Care Guidelines for Small Animal Practice. Long-term Outcome of a Chihuahua With Idiopathic Syndrome of Inappropriate Antidiuretic Hormone Secretion. Outcome, Complications, and Follow-Up in Dogs Treated with Pancarpal Arthrodesis Stabilized with Orthogonal Plates. Successful Management of Incompletely Resected Transitional Cell Carcinoma with Sorafenib Tosylate in a Dog.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1